Firms

INKEF Capital

INKEF Capital

Amsterdam, Netherlands

inkef.com

INKEF Capital is an Amsterdam-based long-term venture investor in healthcare/life sciences and technology. Its current own sustainability disclosure identifies legal INKEF Capital B.V.; official GLEIF identifies active Dutch company50127837, LEI72450026Z98GXUOVRI24 and current Leidsegracht3,1017NAAmsterdam address. Established in2010 with Dutch pension fund ABP backing, the firm supports early-stage companies through technology development, commercialisation and subsequent growth with investment and operational guidance. Its relevant portfolio spans neuromuscular therapeutics (NMD Pharma), neurostimulation (Salvia BioElectronics and ONWARD), AI medical imaging, drug development, enterprise software and silicon-spin quantum computing. ABP’s audited2016 report records its actual commitment increasing by300M to500M inJune2016; government2024 disclosure corroborates500M historical fund commitments. This is committed investment-vehicle capital, not proof paid-in cash or a new2026 LP fund close. Recent550M cumulative deployment references, portfolio fair values and firm AUM are distinct from fundraising. The live current website names eight people with authentic original portraits; old cached versions naming additional staff are not automatically current. Corné Jansen is still listed by INKEF and credited for2026 portfolio work, while Coalition Capital announced him as its General Partner inJune2024; this affiliation is qualified without guessing exclusive employment. Ivan Burkov’s current NMD Pharma General Partner biography and existing Salvia board history/photo are preserved. The firm’s legal corporate identity, fund commitment, institutional portfolio investments and individual professional roles are kept distinct.

Founded
2010
Type
Venture capital

Funds1

  • INKEF Capital — long-term venture investment vehicle€500M

    Historical long-term venture investment vehicle backed by ABP since2010. ABP’s audited2016 annual report explicitly records actual committed capital increasing by300M to500M inJune2016; the2024 Dutch government pension-fund investment table independently corroborates500M commitments across2010–2016. This is published committed vehicle capital, not assertion of paid-in/called cash or a new2026 final LP close. NMD Pharma’s primary investor description identifies20-year fund life and500Mfundsize. Exact closing day and separate legal LP fund name are not publicly established; announcedAtNULL. Initial200M and later300M increase are the same vehicle history, not two duplicated funds;550M cumulative deployment/AUM references excluded.

Team

Operations and support

Cher Shen KiarCher Shen KiarSenior Associate
Corné JansenCorné JansenPartner — published portfolio affiliation; Coalition Capital GP since 2024
Frank LansinkFrank LansinkPartner
Ivan BurkovIvan BurkovPartner
Najma LabyadNajma LabyadFinancial Director
Reitze DoumaReitze DoumaChief Finance & Risk Officer
Ryan SarverRyan SarverPartner
Thijs Cohen TervaertThijs Cohen TervaertPartner

Co-investing

Dolby Family Ventures
Lundbeckfond Invest A/S
Novo Holdings
Roche Venture Fund
Amgen Ventures

Investments

$32M2021-04-22ONWARD MedicalINKEF Capital
$60M2025-05-27Salvia BioElectronicsInnovation Industries, Panakès Partners, Invest-NL, INKEF Capital, Dolby Family Ventures, EIC Fund, Thuja Capital, SHS Capital
€75M2023-11-15NMD PharmaJeito Capital, Novo Holdings, INKEF Capital, Lundbeckfond Invest A/S, Roche Venture Fund
$88M2023-03-09QurAlisDroia Ventures, EQT Life Sciences, Sanofi Ventures, INKEF Capital, Dementia Discovery Fund, Mission BioCapital, Polaris Innovation Fund, Amgen Ventures, ALS Investment Fund, Sanford Biosciences LLC, MP Healthcare Venture Management, Dolby Family Ventures, Mission Bay Capital, Mitsui & Co. Global Investment, Inc.
$50M2022-03-15ChannelEngineGeneral Catalyst, Atomico, Airbridge Equity Partners, INKEF Capital, Luca Eisenstecken, Lawrence Bohn, Max Rimpel
€35M2022-02-15NMD PharmaJeito Capital, Novo Holdings, INKEF Capital, Lundbeckfond Invest A/S, Roche Venture Fund
€21M2020-09-22Salvia BioElectronicsINKEF Capital
$42M2020-05-13QurAlisINKEF Capital, Dementia Discovery Fund, Mission BioCapital, Droia Ventures, Polaris Innovation Fund, Amgen Ventures, Sanford Biosciences LLC, MP Healthcare Venture Management, Dolby Family Ventures, Mitsui & Co. Global Investment, Inc.
€38M2018-03-23NMD PharmaINKEF Capital, Novo Holdings, Lundbeckfond Invest A/S, Roche Venture Fund